Alpha Tau REGAIN Trial Shows 83.3% Complete Response in Glioblastoma

Alpha Tau Medical reported interim REGAIN trial data showing five complete responses among six evaluable recurrent glioblastoma patients. The update also highlighted no unanticipated serious adverse events and 100% treatment deployment success.

Alpha Tau Medical’s interim REGAIN trial update delivered an eye-catching data point for investors and oncology specialists alike: five of six evaluable patients with recurrent glioblastoma achieved complete tumor clearance at the treated site. In percentage terms, that is an 83.3% complete response rate under RANO criteria.

The early-stage U.S. study remains small, with eight patients treated so far, but the initial efficacy signal is notable in one of the most difficult-to-treat brain cancers. Shares of Alpha Tau Medical climbed 15.70% in premarket trading to $15.48 following the announcement, approaching the stock’s 52-week high of $15.79.

The REGAIN trial data cut through November 11, 2026, and showed all six evaluable patients achieved an objective response. For a company developing a localized alpha-radiation platform in recurrent glioblastoma, that combination of tumor response and manageable safety is likely to remain the central focus for the market.

Key Facts

  • Eight patients have been treated in the U.S. REGAIN trial, and six have reached MRI response assessment.
  • All six evaluable patients achieved an objective response, including five complete responses and one partial response with a 58% tumor reduction.
  • All eight treated patients were alive as of November 11, 2026, while median overall survival had not yet been reached.
  • Median follow-up among the six assessed patients was 6.9 months, and no definitive recurrence was seen within the treated zone.
  • Alpha Tau Medical shares rose 15.70% to $15.48 in premarket trading, near a 52-week high of $15.79.

Alpha DaRT therapy in recurrent glioblastoma

The REGAIN trial is evaluating Alpha DaRT therapy in recurrent glioblastoma, an aggressive brain tumor with limited treatment options after relapse. The latest update indicates that all three patients from the company’s May 2026 disclosure ultimately achieved confirmed complete responses, including one patient who initially had stable disease before converting with longer follow-up. That progression matters because it suggests tumor response may deepen over time rather than peak immediately after treatment.

The three newest responses are still early and require subsequent imaging confirmation, which is an important caveat for investors. Small oncology studies often generate strong preliminary signals that later moderate as more patients are enrolled and follow-up extends. Even so, a 100% objective response rate in evaluable patients is difficult for the market to ignore, particularly in recurrent glioblastoma, where durability and local control are major clinical hurdles.

The feasibility profile also supports the development case. Investigators reported successful deployment of planned Alpha DaRT sources in 100% of treated patients, meeting a practical milestone that can be just as important as efficacy in device-enabled cancer therapies. If a treatment cannot be delivered consistently in complex anatomical settings like the brain, commercial potential narrows quickly. In this trial, the company appears to have cleared that early operational bar.

Early REGAIN data suggest Alpha DaRT is generating unusually strong local tumor control in recurrent glioblastoma, but investors will need confirmation in a larger patient set and with longer follow-up.

Safety, imaging questions and what still needs proof

Safety remains a critical lens for evaluating the program. The company reported no unanticipated serious adverse events, and all patients recovered from side effects without lasting procedure-related symptoms. One patient with a prior seizure history experienced a grade 3 seizure with Todd’s paralysis, but the event resolved with steroids after a 48-hour hospital stay. That event does not negate the broader safety signal, though it underscores the high-risk baseline condition of this patient population.

Imaging interpretation may become one of the most important variables in the next phase of analysis. Follow-up scans showed asymptomatic necrosis or suspected necrosis near the treated site in four of six assessed patients. In two patients, investigators are using additional imaging and potentially biopsies to determine whether new enhancement reflects treatment-related necrosis or true tumor progression. That distinction is especially relevant in neuro-oncology, where post-treatment imaging changes can complicate response assessment and affect how investors interpret durability.

Implications for Investors

For investors, the most immediate implication is that Alpha Tau Medical has produced a headline clinical result that could reshape expectations for its oncology platform. Recurrent glioblastoma is a high-unmet-need indication, and even modestly differentiated therapies can attract strategic interest if they demonstrate meaningful tumor control. A complete response rate of 83.3% in evaluable patients, while still based on a small sample, materially strengthens the company’s clinical narrative.

At the same time, biotechnology investors should balance enthusiasm with development-stage risk. The trial is still enrolling toward 20 patients, and the dataset remains immature. Median overall survival has not yet been reached, which is encouraging, but survival durability will matter far more than an early radiographic response alone. Investors should also monitor whether future imaging clarifies the necrosis-versus-progression question, as ambiguous scans can cloud the interpretation of efficacy in brain cancer trials.

Stock reaction also suggests expectations may rise quickly from here. With shares trading at $15.48 in premarket action and near a 52-week high of $15.79, future updates may need to show continued confirmation of complete responses, sustained local control, and acceptable safety to support further upside. Key watch points include additional MRI assessments, enrollment progress, any emerging survival data, and whether treatment effects remain confined to the intended target area without unexpected neurological complications.

The next phase of the REGAIN trial will be crucial in determining whether this interim signal can translate into a more durable investment thesis. If response rates hold as enrollment expands and follow-up lengthens, Alpha DaRT could move into sharper focus as a differentiated approach in recurrent glioblastoma.

Ultima Markets